Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

AI and a simple blood test could spot Alzheimer's years early

NCT ID NCT07402161

Knowledge-focused Sponsor: IRCCS Policlinico S. Donato Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now This study
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study is looking for better, cheaper ways to detect Alzheimer's disease early. Researchers will collect blood samples, brain wave recordings, and speech recordings from 250 people who have noticed memory problems but still function normally. They will use machine learning to combine all this data and see if it can predict who will develop Alzheimer's. The goal is to create a simple screening tool that could be used in regular doctor visits, avoiding expensive and invasive tests.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

What this could lead to
If successful, this could lead to a simple, low-cost way to identify people at high risk for Alzheimer's years before symptoms worsen, allowing earlier access to new treatments.
What could go wrong
This is an observational study, not a treatment trial. The machine-learning model may not prove accurate enough for widespread use, and results may not apply to all populations.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

About 250 people

The number the study aims to enrol. It can still change while the study runs.

Started

Oct 2025

Expected to finish

Mar 2028

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

Participants will be consecutively recruited among patients referred for cognitive disorders to the Neurology Unit (U.O.C.) of IRCCS Policlinico San Donato (hereinafter referred to as UO1) and to the Research and Innovation Center for Dementia (CRIDEM) of the Careggi University Hospital in Florence (AOUC, hereinafter referred to as UO2).

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Clinical diagnosis of SCD according to the SCD-I criteria; * Mini-Mental State Examination (MMSE) score greater than 24, adjusted for age and education level; * Normal functioning on the Activities of Daily Living (ADL) and Instrumental Activities of Daily Living (IADL) scales. Exclusion Criteria: * History of head trauma; * Current neurological and/or systemic diseases; * Symptoms of psychosis, major depression, or substance use disorder.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Subjective cognitive complaints (SCCS) are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

Speech subjective cognitive decline

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Subjective cognitive complaints (SCCS) Subjective cognitive concerns Subjective cognitive decline (SCD) Subjective cognitive impairment Subjective memory complaint Subjective memory decline

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    1 site. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • IRCCS Policlinico San Donato

    RECRUITING

    San Donato Milanese, Milan, 20097, Italy

More trials for these conditions

Other studies related to the condition(s) this trial covers.